Galectin Therapeutics (GALT) Shares Outstanding (Weighted Average) (2010 - 2026)

Galectin Therapeutics' Shares Outstanding (Weighted Average) history runs 17 years deep, the most recent figure standing at $65.8 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 1602.64% year-over-year to $65.8 million; the TTM figure through Mar 2026 stood at $65.8 million (up 1602.64% YoY), while the FY2025 annual figure was $63.9 million, up 565.94% from the prior year.
• Shares Outstanding (Weighted Average) was $65.8 million for Q1 2026 at Galectin Therapeutics, up from $63.9 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $65.8 million in Q1 2026 to a low of $3.9 million in Q1 2025.
• Historically, Shares Outstanding (Weighted Average) has averaged $54.5 million across 5 years, with a median of $59.7 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Weighted Average) slumped 93.77% in 2025, then surged 1602.64% in 2026.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $59.4 million in 2022, then rose by 1.29% to $60.2 million in 2023, then gained by 3.57% to $62.3 million in 2024, then grew by 2.56% to $63.9 million in 2025, then rose by 2.94% to $65.8 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $65.8 million (Q1 2026), $63.9 million (Q4 2025), and $63.6 million (Q3 2025), per Business Quant data.